Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

@article{Erjala2006SignalingVE,
  title={Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells},
  author={Kaisa Erjala and Maria Sundvall and Teemu T. Junttila and Na Zhang and Mika Savisalo and Pekka Mali and J. Kulmala and Jaakko Pulkkinen and Reidar Grénman and Klaus Elenius},
  journal={Clinical Cancer Research},
  year={2006},
  volume={12},
  pages={4103 - 4111}
}
Purpose: The epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) has shown antitumor activity in clinical trials against cancers, such as non–small cell lung cancer and head and neck squamous cell carcinoma (HNSCC). Research on non–small cell lung cancer has elucidated factors that may predict response to gefitinib. Less is known about molecular markers that may predict response to gefitinib in HNSCC patients. Experimental Design: We analyzed possible associations of… 

Figures and Tables from this paper

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib
TLDR
Pancreatic cancer expression of ErbB3 may be useful for EGFR-targeted therapy patient selection and become less critically dependent on EGFR signaling and therefore resistant to erlotinib.
Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer
TLDR
The data demonstrated that co-targeting EGFR and IKKβ with Gefitinib and I Kurdistanβ and CmpdA synergistically enhanced the efficacy of EGFR inhibitors to further inhibit in vitro HNSCC cell growth.
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
TLDR
This study suggests that the vorinostat/gefitinib combination represents a promising therapeutic strategy that warrants further clinical evaluation in SCCHN, including tumors intrinsically resistant to EGFR‐inhibitors.
EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients.
TLDR
Surgery could favor the proliferation of cells showing EGFR overexpression/activation/amplification such as residual tumor cells and/or precursor-field epithelial cells already present after surgery.
Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
TLDR
Results identify Axl as a key mediator of acquired erlotinib resistance in HNC and suggest that therapeutic inhibition of Axl by small molecule drugs or specific miRNAs might overcome anti-EGFR therapy resistance.
Mechanisms of resistance to HER family targeting antibodies.
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
TLDR
Combination treatments increased the efficacy of cetuximab, which may be important for the management of patients with chemorefractory NSCLC, and Exploring the underlying mechanism for combination effects in the H1975 xenograft model, docetaxel in combination with cetUXimab added to the antiproliferative effects of cETuxIMab but was the main component in this drug combination to induce apoptosis.
...
...

References

SHOWING 1-10 OF 66 REFERENCES
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
  • J. AnidoP. Matar J. Baselga
  • Biology, Chemistry
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
TLDR
The effects of ZD1839 in breast cancer cell lines expressing different levels of EGFR and the closely related HER2 receptor suggest that there is a strong rationale to conduct clinical trials of the tyrosine kinase inhibitor in patients with HER2-overexpressing breast tumors.
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
TLDR
Gefitinib treatment decreased EGFR, ERK1/2, and Akt phosphorylation in EGFR mutant cell lines whereas cetuximab had relatively little effect, and EGFR mutations in NSCLC cells are associated with sensitivity to gefit inib but not to cetUXimab.
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
TLDR
This study is the first to show that under basal growth conditions, HER2 sensitizes low-EGFR NSCLC cell lines to growth inhibition by gefitinib, and indicates which molecular target(s) are responsible for limiting the therapeutic efficacy of the drug.
Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines
TLDR
Deregulated cyclin D1 overexpression may be associated with resistance of HNSCC to EGFR inhibitors and its utility as a prognostic marker in H NSCC warrant additional analysis.
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
TLDR
High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC and independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P- akt-, or EGFR-/Akt- patients.
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients
TLDR
Based on upregulation of several known immunosuppressive molecules, scarcity of ErbB‐specific antibodies is consistent with attenuation of natural tumour‐specific immune responses in HNSCC.
Deregulated Cyclin D 1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines
TLDR
Deregulated cyclin D1 overexpression may be associated with resistance of HNSCC to EGFR inhibitors and its utility as a prognostic marker in H NSCC warrant additional analysis.
HER 2 Overexpression Increases Sensitivity to Gefitinib , an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor , through Inhibition of HER 2 / HER 3 Heterodimer Formation in Lung Cancer Cells
TLDR
This study is the first to show that under basal growth conditions, HER2 sensitizes low-EGFR NSCLC cell lines to growth inhibition by gefitinib, and is an orally active, selective EGFR tyrosine kinase inhibitor.
Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR
TLDR
The data indicate that unlike NSCLC, EGFR kinase mutations are rare in unselected cases of SCCHN within the United States and are not linked to gefitinib or erlotinib responses inSCCHN.
...
...